CoChat
Sign Up
Cited by 8

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Rejuvenation Strategy for Inducing and Enhancing Autoimmune Response to Eliminate Senescent Cells

Wang, Xingyue, Zhang, Chengyu, Su, Jiahong, Ren, Siqi, Wang, Xiang, Zhang, Yinping, Yuan, Zijun, He, Xinyu, Wu, Xu, Li, Mingxing, Du, Fukuan, Chen, Yu, Deng, Shuai, Zhao, Yueshui, Wang, Xiaodong, Sun, Yuhong, Shen, Jing, Ji, Huijiao, Hou, Yunqing, Xiao, Zhangang·2025·Aging and disease
DOI 10.14336/ad.2024.0579PMC PMC12221410
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14336/ad.2024.0579

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Immune-based senotherapies inherently carry the risk of immune-related adverse events, including autoimmunity and cytokine release syndrome (CRS).

    “Immune-based senotherapies inherently carry the risk of immune-related adverse events, including autoimmunity and CRS.”

    From Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming (2026) · cites this paper as [118]

    The CAR-T cells section (page unavailable) identifies cytokine release syndrome (CRS) as a prevalent adverse reaction to CAR-T therapy. It does not identify autoimmunity as an adverse event or establish that immune-based senotherapies generally carry both risks; the CAR-NK cells section says CAR-NK cells do not elicit CRS. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • These immune-related risks may be amplified in older patients due to underlying immune dysregulation associated with "inflammaging."

    “These risks may be amplified in older patients due to underlying immune dysregulation associated with “inflammaging.””

    From Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming (2026) · cites this paper as [118]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 144

  1. Prata L, Ovsyannikova IG, Tchkonia T, Kirkland JL (2018). Senescent cell clearance by the immune system: Emerging therapeutic opportunities. Semin Immunol, 40:101275. · DOI · Paper page
  2. Baker DJ, Arany Z, Baur JA, Epstein JA, June CH (2023). CAR T therapy beyond cancer: the evolution of a living drug. Nature, 619:707-715. · DOI
  3. Maslov AY, Vijg J (2009). Genome instability, cancer and aging. Biochim Biophys Acta, 1790:963-969. · DOI
  4. Niedernhofer LJ, Gurkar AU, Wang Y, Vijg J, Hoeijmakers JHJ, Robbins PD (2018). Nuclear Genomic Instability and Aging. Annu Rev Biochem, 87:295-322. · DOI · Paper page
  5. Cejka P, Symington LS (2021). DNA End Resection: Mechanism and Control. Annu Rev Genet, 55:285-307. · DOI
  6. Intano GW, Cho EJ, McMahan CA, Walter CA (2003). Age-related base excision repair activity in mouse brain and liver nuclear extracts. J Gerontol A Biol Sci Med Sci, 58:205-211. · DOI
  7. Simon M, Yang J, Gigas J, Earley EJ, Hillpot E, Zhang L, et al. (2022). A rare human centenarian variant of SIRT6 enhances genome stability and interaction with Lamin A. Embo j, 41:e110393. · DOI · Paper page
  8. Weber B, Allen L, Magenis RE, Goodfellow PJ, Smith L, Hayden MR (1991). Intrachromosomal location of the telomeric repeat (TTAGGG)n. Mamm Genome, 1:211-216. · DOI
  9. Alaguponniah S, Velayudhan Krishna D, Paul S, Christyraj J, Nallaperumal K, Sivasubramaniam S (2020). Finding of novel telomeric repeats and their distribution in the human genome. Genomics, 112:3565-3570. · DOI
  10. Sekne Z, Ghanim GE, van Roon AM, Nguyen THD (2022). Structural basis of human telomerase recruitment by TPP1-POT1. Science, 375:1173-1176. · DOI
  11. Guo J, Huang X, Dou L, Yan M, Shen T, Tang W, et al. (2022). Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduct Target Ther, 7:391. · DOI
  12. Córdoba-Lanús E, Cazorla-Rivero S, Espinoza-Jiménez A, de-Torres JP, Pajares MJ, Aguirre-Jaime A, et al. (2017). Telomere shortening and accelerated aging in COPD: findings from the BODE cohort. Respir Res, 18:59. · DOI
  13. Robin JD, Jacome Burbano MS, Peng H, Croce O, Thomas JL, Laberthonniere C, et al. (2020). Mitochondrial function in skeletal myofibers is controlled by a TRF2-SIRT3 axis over lifetime. Aging Cell, 19:e13097. · DOI
  14. Gibson F, Hanly A, Grbic N, Grunberg N, Wu M, Collard M, et al. (2022). Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases. Clin Rev Allergy Immunol, 63:447-471. · DOI
  15. Wang K, Liu H, Hu Q, Wang L, Liu J, Zheng Z, et al. (2022). Epigenetic regulation of aging: implications for interventions of aging and diseases. Signal Transduct Target Ther, 7:374. · DOI
  16. Yang JH, Hayano M, Griffin PT, Amorim JA, Bonkowski MS, Apostolides JK, et al. (2023). Loss of epigenetic information as a cause of mammalian aging. Cell, 186:305-326. · DOI · Paper page
  17. Horvath S (2013). DNA methylation age of human tissues and cell types. Genome Biol, 14:R115. · DOI · Paper page
  18. Liu B, Qu J, Zhang W, Izpisua Belmonte JC, Liu GH (2022). A stem cell aging framework, from mechanisms to interventions. Cell Rep, 41:111451. · DOI
  19. Francisco S, Ferreira M, Moura G, Soares AR, Santos MAS (2020). Does proteostasis get lost in translation? Implications for protein aggregation across the lifespan. Ageing Res Rev, 62:101119. · DOI
  20. Martinez-Miguel VE, Lujan C, Espie-Caullet T, Martinez-Martinez D, Moore S, Backes C, et al. (2021). Increased fidelity of protein synthesis extends lifespan. Cell Metab, 33:2288-2300. · DOI · Paper page
  21. Rodriguez-Navarro JA, Kaushik S, Koga H, Dall'Armi C, Shui G, Wenk MR, et al. (2012). Inhibitory effect of dietary lipids on chaperone-mediated autophagy. Proc Natl Acad Sci U S A, 109:E705-714. · DOI
  22. Klionsky DJ, Petroni G, Amaravadi RK, Baehrecke EH, Ballabio A, Boya P, et al. (2021). Autophagy in major human diseases. Embo j, 40:e108863. · DOI · Paper page
  23. Dikic I (2017). Proteasomal and Autophagic Degradation Systems. Annu Rev Biochem, 86:193-224. · DOI
  24. Gressler AE, Leng H, Zinecker H, Simon AK (2023). Proteostasis in T cell aging. Semin Immunol, 70:101838. · DOI
  25. Korovila I, Hugo M, Castro JP, Weber D, Höhn A, Grune T, et al. (2017). Proteostasis, oxidative stress and aging. Redox Biol, 13:550-567. · DOI
  26. Tabibzadeh S (2023). Role of autophagy in aging: The good, the bad, and the ugly. Aging Cell, 22:e13753. · DOI
  27. Leidal AM, Levine B, Debnath J (2018). Autophagy and the cell biology of age-related disease. Nat Cell Biol, 20:1338-1348. · DOI · Paper page
  28. Rubinsztein DC, Mariño G, Kroemer G (2011). Autophagy and aging. Cell, 146:682-695. · DOI · Paper page
  29. Pietrocola F, Lachkar S, Enot DP, Niso-Santano M, Bravo-San Pedro JM, Sica V, et al. (2015). Spermidine induces autophagy by inhibiting the acetyltransferase EP300. Cell Death Differ, 22:509-516. · DOI · Paper page
  30. Dellorusso PV, Proven MA, Calero-Nieto FJ, Wang X, Mitchell CA, Hartmann F, et al. (2024). Autophagy counters inflammation-driven glycolytic impairment in aging hematopoietic stem cells. Cell Stem Cell. · DOI
  31. Smith HJ, Sharma A, Mair WB (2020). Metabolic Communication and Healthy Aging: Where Should We Focus Our Energy? Dev Cell, 54:196-211. · DOI
  32. Sung Y, Yu YC, Han JM (2023). Nutrient sensors and their crosstalk. Exp Mol Med, 55:1076-1089. · DOI
  33. Fontana L, Partridge L, Longo VD (2010). Extending healthy life span--from yeast to humans. Science, 328:321-326. · DOI · Paper page
  34. Weaver KJ, Holt RA, Henry E, Lyu Y, Pletcher SD (2023). Effects of hunger on neuronal histone modifications slow aging in Drosophila. Science, 380:625-632. · DOI
  35. Muñoz-Espín D, Serrano M (2014). Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol, 15:482-496. · DOI · Paper page
  36. Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, et al. (2023). Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther, 8:200. · DOI
  37. Weir HJ, Yao P, Huynh FK, Escoubas CC, Goncalves RL, Burkewitz K, et al. (2017). Dietary Restriction and AMPK Increase Lifespan via Mitochondrial Network and Peroxisome Remodeling. Cell Metab, 26:884-896. · DOI · Paper page
  38. Victorelli S, Salmonowicz H, Chapman J, Martini H, Vizioli MG, Riley JS, et al. (2023). Apoptotic stress causes mtDNA release during senescence and drives the SASP. Nature, 622:627-636. · DOI
  39. Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, et al. (2022). Stem cell-based therapy for human diseases. Signal Transduct Target Ther, 7:272. · DOI · Paper page
  40. Zhu Y, Ge J, Huang C, Liu H, Jiang H (2021). Application of mesenchymal stem cell therapy for aging frailty: from mechanisms to therapeutics. Theranostics, 11:5675-5685. · DOI
  41. Xiao X, Xu M, Yu H, Wang L, Li X, Rak J, et al. (2021). Mesenchymal stem cell-derived small extracellular vesicles mitigate oxidative stress-induced senescence in endothelial cells via regulation of miR-146a/Src. Signal Transduct Target Ther, 6:354. · DOI
  42. Fafián-Labora JA, O'Loghlen A (2020). Classical and Nonclassical Intercellular Communication in Senescence and Ageing. Trends Cell Biol, 30:628-639. · DOI
  43. Wright WE, Shay JW (2002). Historical claims and current interpretations of replicative aging. Nat Biotechnol, 20:682-688. · DOI
  44. Collins CJ, Sedivy JM (2003). Involvement of the INK4a/Arf gene locus in senescence. Aging Cell, 2:145-150. · DOI · Paper page
  45. Zhang P, Catterson JH, Grönke S, Partridge L (2024). Inhibition of S6K lowers age-related inflammation and increases lifespan through the endolysosomal system. Nat Aging. · DOI
  46. Di Giosia P, Stamerra CA, Giorgini P, Jamialahamdi T, Butler AE, Sahebkar A (2022). The role of nutrition in inflammaging. Ageing Res Rev, 77:101596. · DOI
  47. Bai Z, Liu Y, Zhao Y, Yan R, Yang L, Ma H, et al. (2023). Aspirin ameliorates atherosclerotic immuno-inflammation through regulating the Treg/Th17 axis and CD39-CD73 adenosine signaling via remodeling the gut microbiota in ApoE(-/-) mice. Int Immunopharmacol, 120:110296. · DOI
  48. Hou Q, Huang J, Ayansola H, Masatoshi H, Zhang B (2020). Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases. Front Immunol, 11:623691. · DOI
  49. Haran JP, McCormick BA (2021). Aging, Frailty, and the Microbiome-How Dysbiosis Influences Human Aging and Disease. Gastroenterology, 160:507-523. · DOI
  50. Doifode T, Giridharan VV, Generoso JS, Bhatti G, Collodel A, Schulz PE, et al. (2021). The impact of the microbiota-gut-brain axis on Alzheimer's disease pathophysiology. Pharmacol Res, 164:105314. · DOI · Paper page
  51. Adhikary S, Esmeeta A, Dey A, Banerjee A, Saha B, Gopan P, et al. (2024). Impacts of gut microbiota alteration on age-related chronic liver diseases. Dig Liver Dis, 56:112-122. · DOI
  52. Saint-Criq V, Lugo-Villarino G, Thomas M (2021). Dysbiosis, malnutrition and enhanced gut-lung axis contribute to age-related respiratory diseases. Ageing Res Rev, 66:101235. · DOI
  53. Du Y, Gao Y, Zeng B, Fan X, Yang D, Yang M (2021). Effects of anti-aging interventions on intestinal microbiota. Gut Microbes, 13:1994835. · DOI
  54. Giron M, Thomas M, Dardevet D, Chassard C, Savary-Auzeloux I (2022). Gut microbes and muscle function: can probiotics make our muscles stronger? J Cachexia Sarcopenia Muscle, 13:1460-1476. · DOI
  55. Sharma R (2022). Emerging Interrelationship Between the Gut Microbiome and Cellular Senescence in the Context of Aging and Disease: Perspectives and Therapeutic Opportunities. Probiotics Antimicrob Proteins, 14:648-663. · DOI
  56. Johmura Y, Yamanaka T, Omori S, Wang TW, Sugiura Y, Matsumoto M, et al. (2021). Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders. Science, 371:265-270. · DOI · Paper page
  57. Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, et al. (2024). Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat Aging, 4:336-349. · DOI · Paper page
  58. Bartley JM, Xu M (2024). Unleashing CAR T cells to delay metabolic aging. Nat Aging, 4:284-286. · DOI
  59. López-Otín C, Pietrocola F, Roiz-Valle D, Galluzzi L, Kroemer G (2023). Meta-hallmarks of aging and cancer. Cell Metab, 35:12-35. · DOI · Paper page
  60. Wang TW, Johmura Y, Suzuki N, Omori S, Migita T, Yamaguchi K, et al. (2022). Blocking PD-L1-PD-1 improves senescence surveillance and ageing phenotypes. Nature, 611:358-364. · DOI · Paper page
  61. Onorati A, Havas AP, Lin B, Rajagopal J, Sen P, Adams PD, et al. (2022). Upregulation of PD-L1 in Senescence and Aging. Mol Cell Biol, 42:e0017122. · DOI
  62. Rivera N, Boada A, Bielsa MI, Fernández-Figueras MT, Carcereny E, Moran MT, et al. (2017). Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer. JAMA Dermatol, 153:1162-1165. · DOI
  63. Manson G, Marabelle A, Houot R (2018). Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis. JAMA Dermatol, 154:113. · DOI
  64. Zou Y, Gan CL, Xin Z, Zhang HT, Zhang Q, Lee TH, et al. (2021). Programmed Cell Death Protein 1 Blockade Reduces Glycogen Synthase Kinase 3β Activity and Tau Hyperphosphorylation in Alzheimer's Disease Mouse Models. Front Cell Dev Biol, 9:769229. · DOI
  65. Ghareghani M, Rivest S (2023). The Synergistic Potential of Combining PD-1/PD-L1 Immune Checkpoint Inhibitors with NOD2 Agonists in Alzheimer's Disease Treatment. Int J Mol Sci, 24:10905. · DOI
  66. Zhang P, Wang Y, Miao Q, Chen Y (2023). The therapeutic potential of PD-1/PD-L1 pathway on immune-related diseases: Based on the innate and adaptive immune components. Biomed Pharmacother, 167:115569. · DOI
  67. Shapiro MR, Dong X, Perry DJ, McNichols JM, Thirawatananond P, Posgai AL, et al. (2023). Human immune phenotyping reveals accelerated aging in type 1 diabetes. JCI Insight, 8:e170767. · DOI
  68. Majewska J, Agrawal A, Mayo A, Roitman L, Chatterjee R, Kralova J, et al. (2023). p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells. bioRxiv · DOI
  69. Suda M, Paul KH, Minamino T, Miller JD, Lerman A, Ellison-Hughes GM, et al. (2023). Senescent Cells: A Therapeutic Target in Cardiovascular Diseases. Cells, 12:1296. · DOI
  70. Sansoni P, Cossarizza A, Brianti V, Fagnoni F, Snelli G, Monti D, et al. (1993). Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood, 82:2767-2773. · DOI
  71. Rodríguez-Agustín A, Casanova V, Grau-Expósito J, Sánchez-Palomino S, Alcamí J, Climent N (2023). Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging. Pharmaceutics, 15:917. · DOI
  72. Shin E, Bak SH, Park T, Kim JW, Yoon SR, Jung H, et al. (2023). Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond. Front Immunol, 14:1192907. · DOI
  73. Liu X, Song J, Zhang H, Liu X, Zuo F, Zhao Y, et al. (2023). Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell, 41:272-287. · DOI
  74. Niu C, Jin H, Li M, Zhu S, Zhou L, Jin F, et al. (2017). Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma. Oncotarget, 8:5954-5964. · DOI
  75. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, et al. (2009). ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood, 113:3503-3511. · DOI · Paper page
  76. Etxebeste-Mitxeltorena M, Del Rincón-Loza I, Martín-Antonio B (2021). Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner. Front Immunol, 12:717850. · DOI
  77. Carrasco E, Gómez de Las Heras MM, Gabandé-Rodríguez E, Desdín-Micó G, Aranda JF, Mittelbrunn M (2022). The role of T cells in age-related diseases. Nat Rev Immunol, 22:97-111. · DOI
  78. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. (2011). Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature, 479:547-551. · DOI · Paper page
  79. Hasegawa T, Oka T, Son HG, Oliver-García VS, Azin M, Eisenhaure TM, et al. (2023). Cytotoxic CD4(+) T cells eliminate senescent cells by targeting cytomegalovirus antigen. Cell, 186:1417-1431. · DOI
  80. Chen HA, Ho YJ, Mezzadra R, Adrover JM, Smolkin R, Zhu C, et al. (2023). Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity. Cancer Discov, 13:432-453. · DOI
  81. DeJong EN, Surette MG, Bowdish DME (2020). The Gut Microbiota and Unhealthy Aging: Disentangling Cause from Consequence. Cell Host Microbe, 28:180-189. · DOI · Paper page
  82. Ruf B, Greten TF, Korangy F (2023). Innate lymphoid cells and innate-like T cells in cancer - at the crossroads of innate and adaptive immunity. Nat Rev Cancer, 23:351-371. · DOI
  83. Kurioka A, Klenerman P (2023). Aging unconventionally: γδ T cells, iNKT cells, and MAIT cells in aging. Semin Immunol, 69:101816. · DOI
  84. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. (1997). CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science, 278:1626-1629. · DOI · Paper page
  85. Qin Y, Bao X, Zheng M (2022). CD8(+) T-cell immunity orchestrated by iNKT cells. Front Immunol, 13:1109347. · DOI
  86. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L (2008). CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr Opin Immunol, 20:358-368. · DOI
  87. Loh L, Ivarsson MA, Michaëlsson J, Sandberg JK, Nixon DF (2014). Invariant natural killer T cells developing in the human fetus accumulate and mature in the small intestine. Mucosal Immunol, 7:1233-1243. · DOI
  88. Li YR, Zhou Y, Kim YJ, Zhu Y, Ma F, Yu J, et al. (2021). Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep Med, 2:100449. · DOI
  89. Chen S, Saeed A, Liu Q, Jiang Q, Xu H, Xiao GG, et al. (2023). Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther, 8:207. · DOI
  90. Horiba S, Kami R, Tsutsui T, Hosoi J (2022). IL-34 Downregulation–Associated M1/M2 Macrophage Imbalance Is Related to Inflammaging in Sun-Exposed Human Skin. JID Innov, 2:100112. · DOI
  91. Egashira M, Hirota Y, Shimizu-Hirota R, Saito-Fujita T, Haraguchi H, Matsumoto L, et al. (2017). F4/80+ Macrophages Contribute to Clearance of Senescent Cells in the Mouse Postpartum Uterus. Endocrinology, 158:2344-2353. · DOI · Paper page
  92. Srivastava S, Riddell SR (2015). Engineering CAR-T cells: Design concepts. Trends Immunol, 36:494-502. · DOI
  93. Hughes-Parry HE, Cross RS, Jenkins MR (2019). The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells. Int J Mol Sci, 21:204. · DOI
  94. Barden M, Holzinger A, Velas L, Mezősi-Csaplár M, Szöőr Á, Vereb G, et al. (2023). CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation. Front Immunol, 14:1110482. · DOI
  95. Alabanza LM, Pegues MA, Geldres C, Shi V, Kochenderfer JN (2016). 74. The Impact of Different Hinge and Transmembrane Components on the Function of a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor. Molecular Therapy, 24: S32-S33. · DOI
  96. Wu W, Zhou Q, Masubuchi T, Shi X, Li H, Xu X, et al. (2020). Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy. Cell, 182:855-871. · DOI
  97. Riley RS, June CH, Langer R, Mitchell MJ (2019). Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov, 18:175-196. · DOI
  98. Vairy S, Garcia JL, Teira P, Bittencourt H (2018). CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug Des Devel Ther, 12:3885-3898. · DOI
  99. Smirnov S, Mateikovich P, Samochernykh K, Shlyakhto E (2024). Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic. Front Immunol, 15:1335424. · DOI
  100. Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, et al. (2022). Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol, 19:342-355. · DOI
  101. Lu J, Jiang G (2022). The journey of CAR-T therapy in hematological malignancies. Mol Cancer, 21:194. · DOI
  102. Dimitri A, Herbst F, Fraietta JA (2022). Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer, 21:78. · DOI
  103. Rettko NJ, Campisi J, Wells JA (2022). Engineering Antibodies Targeting p16 MHC-Peptide Complexes. ACS Chem Biol, 17:545-555. · DOI
  104. Wang L, Matsumoto M, Akahori Y, Seo N, Shirakura K, Kato T, et al. (2024). Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4(p230-239)/HLA-A∗02:01 complex. Mol Ther, 32:734-748. · DOI
  105. Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, et al. (2023). Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Res Sq. Nat Aging. 4:336-349. · DOI · Paper page
  106. Yang D, Sun B, Li S, Wei W, Liu X, Cui X, et al. (2023). NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates. Sci Transl Med, 15:eadd1951. · DOI · Paper page
  107. Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, et al. (2019). Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res, 7:100-112. · DOI
  108. Morris EC, Neelapu SS, Giavridis T, Sadelain M (2022). Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol, 22:85-96. · DOI
  109. Totzeck M, Michel L, Lin Y, Herrmann J, Rassaf T (2022). Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J, 43:1928-1940. · DOI
  110. Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, et al. (2021). Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. J Am Coll Cardiol, 78:1800-1813. · DOI
  111. Kotch C, Barrett D, Teachey DT (2019). Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol, 15:813-822. · DOI
  112. Hernani R, Aiko M, Victorio R, Benzaquén A, Pérez A, Piñana JL, et al. (2024). EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome. Clin Neurophysiol, 163:132-142. · DOI
  113. Gust J, Taraseviciute A, Turtle CJ (2018). Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. CNS Drugs, 32:1091-1101. · DOI
  114. Neelapu SS (2019). Managing the toxicities of CAR T-cell therapy. Hematol Oncol, 37 Suppl 1:48-52. · DOI
  115. Liu Y, An L, Huang R, Xiong J, Yang H, Wang X, et al. (2022). Strategies to enhance CAR-T persistence. Biomark Res, 10:86. · DOI · Paper page
  116. Wei W, Chen ZN, Wang K (2023). CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. Int J Mol Sci, 24:12317. · DOI
  117. Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, et al. (2023). CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer Discov, 13:580-597. · DOI
  118. Liu S, Deng B, Yin Z, Lin Y, An L, Liu D, et al. (2021). Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol, 96:671-679. · DOI
  119. Tang Y, Yin H, Zhao X, Jin D, Liang Y, Xiong T, et al. (2022). High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. J Exp Clin Cancer Res, 41:2. · DOI · Paper page
  120. Myers JA, Miller JS (2021). Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol, 18:85-100. · DOI
  121. Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, et al. (2021). NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J, 11:146. · DOI · Paper page
  122. Berrien-Elliott MM, Jacobs MT, Fehniger TA (2023). Allogeneic natural killer cell therapy. Blood, 141:856-868. · DOI
  123. Kilgour MK, Bastin DJ, Lee SH, Ardolino M, McComb S, Visram A (2023). Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy. Front Immunol, 14:1166038. · DOI
  124. Sloas C, Gill S, Klichinsky M (2021). Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. Front Immunol, 12:783305. · DOI
  125. Zhou Z, Yao J, Wu D, Huang X, Wang Y, Li X, et al. (2024). Type 2 cytokine signaling in macrophages protects from cellular senescence and organismal aging. Immunity. · DOI
  126. Lee H, Sahin GS, Chen CW, Sonthalia S, Cañas SM, Oktay HZ, et al. (2023). Stress-induced β cell early senescence confers protection against type 1 diabetes. Cell Metab, 35:2200-2215. · DOI
  127. Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. (2020). Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol, 38:947-953. · DOI · Paper page
  128. Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. (2023). CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer, 22:20. · DOI
  129. Fang FC (2011). Antimicrobial actions of reactive oxygen species. mBio, 2:e00141-11. · DOI
  130. Exley M, Garcia J, Wilson SB, Spada F, Gerdes D, Tahir SM, et al. (2000). CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology, 100:37-47. · DOI
  131. Rowan AG, Ponnusamy K, Ren H, Taylor GP, Cook LBM, Karadimitris A (2023). CAR-iNKT cells targeting clonal TCRVβ chains as a precise strategy to treat T cell lymphoma. Front Immunol, 14:1118681. · DOI
  132. O'Neal J, Cooper ML, Ritchey JK, Gladney S, Niswonger J, González LS, et al. (2023). Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc. Blood Adv, 7:6009-6022. · DOI
  133. Exley MA, Hou R, Shaulov A, Tonti E, Dellabona P, Casorati G, et al. (2008). Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur J Immunol, 38:1756-1766. · DOI
  134. Gao Y, Guo J, Bao X, Xiong F, Ma Y, Tan B, et al. (2021). Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial. Oncologist, 26:e1919-e1930. · DOI
  135. Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, et al. (2024). Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat Aging. · DOI
  136. Yoshida S, Nakagami H, Hayashi H, Ikeda Y, Sun J, Tenma A, et al. (2020). The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. Nat Commun, 11:2482. · DOI · Paper page
  137. Poblocka M, Bassey AL, Smith VM, Falcicchio M, Manso AS, Althubiti M, et al. (2021). Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker. Sci Rep, 11:20358. · DOI · Paper page
  138. Cui H, Xie N, Banerjee S, Dey T, Liu RM, Antony VB, et al. (2022). CD38 Mediates Lung Fibrosis by Promoting Alveolar Epithelial Cell Aging. Am J Respir Crit Care Med, 206:459-475. · DOI
  139. Althubiti M, Lezina L, Carrera S, Jukes-Jones R, Giblett SM, Antonov A, et al. (2014). Characterization of novel markers of senescence and their prognostic potential in cancer. Cell Death Dis, 5:e1528. · DOI · Paper page
  140. Zhang L, Yang P, Chen J, Chen Z, Liu Z, Feng G, et al. (2023). CD44 connects autophagy decline and ageing in the vascular endothelium. Nat Commun, 14:5524. · DOI · Paper page
  141. Frescas D, Roux CM, Aygun-Sunar S, Gleiberman AS, Krasnov P, Kurnasov OV, et al. (2017). Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody. Proc Natl Acad Sci U S A, 114:E1668-e1677. · DOI · Paper page
  142. Jia C, Ke-Hong C, Fei X, Huan-Zi D, Jie Y, Li-Ming W, et al. (2020). Decoy receptor 2 mediation of the senescent phenotype of tubular cells by interacting with peroxiredoxin 1 presents a novel mechanism of renal fibrosis in diabetic nephropathy. Kidney Int, 98:645-662. · DOI
  143. Schloesser D, Lindenthal L, Sauer J, Chung KJ, Chavakis T, Griesser E, et al. (2023). Senescent cells suppress macrophage-mediated corpse removal via upregulation of the CD47-QPCT/L axis. J Cell Biol, 222:e202207097. · DOI
  144. Lelarge V, Capelle R, Oger F, Mathieu T, Le Calvé B (2024). Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment. NPJ Aging, 10:12. · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Wang, X., Zhang, C., Su, J., Ren, S., Wang, X., Zhang, Y., Yuan, Z., He, X., Wu, X., Li, M., Du, F., Chen, Y., Deng, S., Zhao, Y., Wang, X., Sun, Y., Shen, J., Ji, H., Hou, Y., & Xiao, Z.
Venue
Aging and disease
Publisher
Aging and Disease
Published
2025
Volume
16
Issue
4
Pages
2273
ISSN
2152-5250
DOI
10.14336/ad.2024.0579
PMC
PMC12221410
Cited by
8
References
46
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review